Skip to main content
. 2018 Jan 1;27(1):10–22. doi: 10.1089/scd.2017.0132

FIG. 1.

FIG. 1.

hiPSC reprogramming and characterization. (A) Experimental timeline for the reprogramming of PBMCs and ECs into hiPSCs. Cell morphology observed during the reprogramming of PBMCs at days 4, 9, and 17 (scale bar = 100 μm). (B) Immunofluorescence staining for the pluripotency markers Oct3/4, Sox2, and Nanog in hiPSCs (scale bar = 200 μm). (C) Flow cytometry-based detection of the pluripotency markers SSEA-4, Tra-1-60, and Tra-1-81 in hiPSCs. (D) Teratoma formation in immunodeficient mice after transplantation of hiPSCs; teratomas contained tissues from all three germ layers. ECs, endothelial cells; hiPSC, human induced pluripotent stem cell; PBMCs, peripheral blood mononuclear cells. Color images are available online at www.libeberpub.com/scd